A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Tomivosertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Effector Therapeutics
- 11 Dec 2018 According to an eFFECTOR Therapeutics media release, the first patient has been dosed in the trial. The company expects to report interim data from this study in the first half of 2019.
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 05 Oct 2018 New trial record